ArticleCureus2026
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Waldenström macroglobulinemia (WM) is a clonal B-cell lymphoproliferative disorder characterized by the presence of monoclonal IgM paraprotein. The traditional treatment approach was chemotherapy in combination with an anti-CD20 antibody. However, the treatment approach underwent a paradigm shift with the approval of Bruton tyrosine kinase inhibitors (BTKis). This retrospective analysis aims to highlight the efficacy and safety of BTKis in WM. Methodology Medical records of patients with WM who received BTKis were retrospectively reviewed. Relevant details regarding demographics, clinical and laboratory investigations, imaging reports, treatment, post-treatment response, adverse events, and infection were extracted from electronic medical records. Descriptive statistics and categorical variables were presented as frequencies and percentages. Survival outcomes were estimated by the Kaplan-Meier method. Results In total, 22 patients received BTKis. Of these, 12 patients received ibrutinib, whereas 10 patients received acalabrutinib. The median age was 64 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.